Psilocybin is emerging as a serious treatment candidate for alcohol use disorder, a condition affecting 27.1 million adults in the U.S., by restoring brain signaling tied to self-control and decision-making. In clinical trials summarized here, psilocybin-assisted therapy cut heavy drinking days and average alcohol intake with medium-to-large effect sizes (Cohen’s d > 0.8), performing on par with or better than many existing medications. This positions psilocybin as a legitimate next-generation option alongside GLP-1 drugs and other precision treatments, not a fringe alternative.